Evaluation of an Oral Anti-TNF Antibody in Patients With Active Ulcerative Colitis

NCT ID: NCT01759056

Last Updated: 2014-03-05

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1
• Total Enrollment: 33 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2013-02-28
• Study Completion Date: 2013-12-31

Brief Summary

The purpose of this study is to evaluate the safety and tolerability as well as the pharmacodynamic effects of multiple doses of AVX-470 administered orally in patients with active ulcerative colitis.

Detailed Description

There is a significant unmet medical need for effective oral pharmacologic therapies for inflammatory bowel diseases such as ulcerative colitis. Current anti-TNF therapies, including infliximab and adalimumab, are effective treatments for these conditions, but they must be administered by intravenous or subcutaneous injection. The major safety concerns associated with the use of injectable anti-TNF therapies are infection, demyelinating disease, and lymphoma, all of which are the result of systemic exposure. These uncommon but serious side effects have limited the use of systemic anti-TNF antibody therapy to patients with severe disease that have failed to respond to first-line treatments.

AVX-470 is purified immunoglobulin (Ig) from the colostrum (early milk) of cows immunized with recombinant human tumor necrosis factor (rhTNF). AVX-470 is formulated in delayed-release enteric-coated capsules designed to protect the capsule contents from gastric acids following oral administration and to provide localized delivery to sites of inflammation in the distal intestine. Prior clinical experience with bovine Ig therapies in other human diseases suggests that AVX-470 will not be absorbed to any significant extent, meaning that systemic exposure could be minimized. The development of oral anti-TNF therapy targeting local intestinal disease activity might reduce the risks associated with injectable anti-TNF therapy and allow the convenience of oral dosing.

The present study is a first-in-human, Phase 1 clinical study. It is primarily intended to evaluate the safety and tolerability of multiple doses of AVX-470 administered orally to patients with active ulcerative colitis.

Animal models of ulcerative colitis using a mouse-specific TNF antibody derived from bovine colostrum demonstrated a 50% or more reduction in tissue TNF, TNF-messenger ribonucleic acid (mRNA), interleukin (IL)-6 mRNA, and myeloperoxidase and lowering of colonic inflammatory activity. Twenty-eight-day toxicology studies demonstrated no clinical or histologic findings in exposures above the intended clinical dose range.

Conditions

Ulcerative Colitis

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: DOUBLE

Study Groups

AVX 470

AVX 470 0.2 g(Cohort 1), 1.6 g (Cohort 2) and 3.5 g (Cohort 3) will be administered daily for 28 days

Group Type: ACTIVE_COMPARATOR

AVX 470

Intervention Type: DRUG

active comparator

Placebo

Placebo will be administered daily for 28 days as a comparator with AVX-470 (all dose groups)

Group Type: PLACEBO_COMPARATOR

Placebo

Intervention Type: DRUG

Interventions

AVX 470

active comparator

Intervention Type: DRUG

Placebo

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• Men or women aged 18 75, inclusive
• Established diagnosis of ulcerative colitis involving the sigmoid colon or proximal segments of bowel
• Total Mayo score between 5-12, inclusive, with endoscopic subscore of the Mayo score ≥ 2 and > 15 cm of involvement beyond the anal verge

Exclusion Criteria

• Women with a positive pregnancy test, who are breastfeeding, or who intend to become pregnant during the course of the study
• Diagnosis of Crohn's disease, microscopic colitis or indeterminate colitis
• Presence of ileostomy or colostomy, or history of prior colon resection
• Patients with planned hospitalization or surgery during the course of the study
• Known allergy to milk proteins, red meat or cornstarch
• Stools positive for enteric infection, including parasitic, or C. difficile toxin within 28 days of screening
• Documented presence of Hetatitis B (HBsAg), Hepatitis C (HCV), or HIV
• Presence of dysplasia of any grade on colonoscopic biopsies
• Treatment for cancer (excluding non-melanomatous cancer of the skin or cervical carcinoma in situ) or lymphoproliferative disorder (including lymphoma) within 5 years
• History of tuberculosis (TB) or Listeria infection, or known exposure to another person with active TB disease within 12 weeks of screening; or history of past or current infection with different opportunistic infections
• History of TNF inhibitor (infliximab, adalimumab or certolizumab pegol) use with primary treatment failure. Secondary treatment failures due to intolerance, allergic reaction, or loss of response will not constitute a basis for exclusion. Oral immunosuppressives, mesalamine, and corticosteroids (up to 20mg of prednisone per day) will be permitted so long as these medications are stable for defined periods of time before study participation commences.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 75 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Avaxia Biologics, Incorporated

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Scott Harris, MD

Role: STUDY_DIRECTOR

Avaxia Biologics, Incorporated

Locations

Anaheim Clinical Trials

Anaheim, California, United States

Rocky Mountain Gastroenterology Associates

Lakewood, Colorado, United States

Shafran Gastroenterology Center

Winter Park, Florida, United States

Chevy Chase Clinical Research

Chevy Chase, Maryland, United States

Clinical Research Institute of Michigan

Chesterfield, Michigan, United States

Center for Digestive and Liver Disease

Mexico, Missouri, United States

Remington-Davis, Inc.

Columbus, Ohio, United States

Oklahoma Foundation for Digestive Research

Oklahoma City, Oklahoma, United States

Nashville Medical Research Institute

Nashville, Tennessee, United States

Gastro-Enterologie

Ghent, , Belgium

Gastro-enterologie

Leuven, , Belgium

The Northern Alberta Clinical Trials and Research Centre

Edmonton, Alberta, Canada

Toronto Digestive Disease Associates

Toronto, Ontario, Canada

Semmelweis Egyetem

Budapest, , Hungary

Debreceni Egyetem Orvos- és Egészségtudományi Centrum

Debrecen, , Hungary

Kenézy Kórház Rendelöintézet Egészségügyi Szolgáltató Kft.

Debrecen, , Hungary

Countries

United States; Belgium; Canada; Hungary

References

Harris MS, Hartman D, Lemos BR, Erlich EC, Spence S, Kennedy S, Ptak T, Pruitt R, Vermeire S, Fox BS. AVX-470, an Orally Delivered Anti-Tumour Necrosis Factor Antibody for Treatment of Active Ulcerative Colitis: Results of a First-in-Human Trial. J Crohns Colitis. 2016 Jun;10(6):631-40. doi: 10.1093/ecco-jcc/jjw036. Epub 2016 Jan 28.

Reference Type: DERIVED

PMID: 26822613 (View on PubMed)

Hartman DS, Tracey DE, Lemos BR, Erlich EC, Burton RE, Keane DM, Patel R, Kim S, Bhol KC, Harris MS, Fox BS. Effects of AVX-470, an Oral, Locally Acting Anti-Tumour Necrosis Factor Antibody, on Tissue Biomarkers in Patients with Active Ulcerative Colitis. J Crohns Colitis. 2016 Jun;10(6):641-9. doi: 10.1093/ecco-jcc/jjw026. Epub 2016 Jan 22.

Reference Type: DERIVED

PMID: 26802087 (View on PubMed)

Other Identifiers

2012-004850-27

Identifier Type: EUDRACT_NUMBER

Identifier Source: secondary_id

AB1101

Identifier Type: -

Identifier Source: org_study_id